Rheumatology Medical News about systemic sclerosis-related pulmonary arterial hypertension;natriuretic peptides

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Natriuretic peptides in systemic sclerosis-related pulmonary arterial hypertension
Seminars in Arthritis and Rheumatism, 06/23/09

Dimitroulas T et al. – Study concludes that systemic sclerosis (SSc) patients, particularly those with pulmonary arterial hypertension (PAH), have a derangement of the neurohormonal system, which worsens with disease severity and disease progression. Natriuretic peptides (NP) seem to be suitable noninvasive biomarkers for SSc PAH patients in terms of screening, diagnostic evaluation, risk stratification, and response to therapy, and this merits prospective evaluation.

Methods

Review to examine the evidence for the physiologic, diagnostic, and prognostic role of NP in the context of SSc PAH
Medline search for articles published between Jan 1999 and Dec 2008
Keywords: natriuretic peptides, systemic sclerosis or scleroderma, and pulmonary arterial hypertension

Results

In pts with SSc PAH, NP levels increase in proportion to the extent of right ventricular dysfunction
They correlate significantly with functional capacity and echocardiographic and hemodynamic parameters
NP may also provide prognostic information beyond conventional risk markers
However, their use has to be considered against the background of the parameters that may influence their concentration

<< Previous
A double-blind, randomized, saline-controlled study of the...

Next >>
Use of risk stratification to target therapies in patients with...

Measures of Response in Clinical Trials of Systemic Sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS)
Journal of Rheumatology, 10/15/09 Relevance Score: 89%

Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis
Internal Medicine Journal, 10/21/09 Relevance Score: 88%

Is pulmonary arterial hypertension really a late complication of systemic sclerosis
Chest, 10/12/09 Relevance Score: 86%

New finding could lead to cure of pulmonary arterial hypertension
Internet Source, 10/26/09 Relevance Score: 82%

Inhibitory Effects of Simvastatin on Platelet-derived Growth Factor Signaling in Pulmonary Artery Smooth Muscle Cells from Patients with Idiopathic Pulmonary Arterial Hypertension
Journal of Cardiovascular Pharmacology, 10/12/09 Relevance Score: 81%